In vivo model with targeted cAMP biosensor reveals changes in receptor-microdomain communication in cardiac disease

Nature Communications

Volumn 6, Issue , 2015, Pages

  Sprenger, Julia U ^a,b   Perera, Ruwan K ^a,b   Steinbrecher, Julia H ^a   Lehnart, Stephan E ^a,c   Maier, Lars S ^d   Hasenfuss, Gerd ^a,c   Nikolaev, Viacheslav O ^a,b,c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; CYCLIC AMP; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SPLEEN EXONUCLEASE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM BINDING PROTEIN; EPAC PROTEIN, MOUSE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; ISOPRENALINE; PHOSPHOLAMBAN;

CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; HYPERTROPHIC ENVIRONMENT; REAL TIME; RODENT; SENSOR;

ADULT; ANIMAL CELL; ARTICLE; BIOCOMPATIBILITY; BIOSENSOR; CONTROLLED STUDY; HEART DISEASE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; MODEL; MOLECULAR DYNAMICS; MONITORING; MOUSE; NONHUMAN; SECOND MESSENGER; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ANIMAL; CARDIOMEGALY; CELL CULTURE; DISEASE MODEL; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC PROCEDURES; HEART DISEASES; METABOLISM; RANDOMIZATION;

MUS MUSCULUS;

ADRENERGIC BETA-AGONISTS; ANIMALS; BIOSENSING TECHNIQUES; CALCIUM-BINDING PROTEINS; CARDIOMEGALY; CELLS, CULTURED; CYCLIC AMP; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEART DISEASES; ISOPROTERENOL; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PHOSPHORIC DIESTER HYDROLASES; RANDOM ALLOCATION; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84929094879     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7965     Document Type: Article

References (42)

1. Fischmeister, R. et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ. Res. 99, 816-828 (2006).
2. Perera, R. K. & Nikolaev, V. O. Compartmentation of cAMP signalling in cardiomyocytes in health and disease. Acta Physiol. (Oxf) 207, 650-662 (2013).
3. Zaccolo, M. cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br. J. Pharmacol. 158, 50-60 (2009).
4. Bers, D. M. Cardiac excitation-contraction coupling. Nature 415, 198-205 (2002).
5. MacLennan, D. H. & Kranias, E. G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566-577 (2003).
6. Buxton, I. L. & Brunton, L. L. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J. Biol. Chem. 258, 10233-10239 (1983).
7. Diviani, D., Dodge-Kafka, K. L., Li, J. & Kapiloff, M. S. A-kinase anchoring proteins: scaffolding proteins in the heart. Am. J. Physiol. Heart Circ. Physiol. 301, H1742-H1753 (2011).
8. Mauban, J. R., O'Donnell, M., Warrier, S., Manni, S. & Bond, M. AKAPscaffolding proteins and regulation of cardiac physiology. Physiol. (Bethesda) 24, 78-87 (2009).
9. Zaccolo, M. & Movsesian, M. A. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res. 100, 1569-1578 (2007).
10. Conti, M. & Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511 (2007).
11. Houslay, M. D., Baillie, G. S. & Maurice, D. H. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ. Res. 100, 950-966 (2007).
12. Scott, J. D., Dessauer, C. W. & Tasken, K. Creating order from chaos: cellular regulation by kinase anchoring. Annu. Rev. Pharmacol. Toxicol. 53, 187-210 (2013).
13. Lompre, A. M. et al. Ca2+ cycling and new therapeutic approaches for heart failure. Circulation 121, 822-830 (2010).
14. Sprenger, J. U. & Nikolaev, V. O. Biophysical techniques for detection of cAMP and cGMP in living cells. Int. J. Mol. Sci. 14, 8025-8046 (2013).
15. Hasenfuss, G. et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ. Res. 75, 434-442 (1994).
16. Nikolaev, V. O., Bunemann, M., Hein, L., Hannawacker, A. & Lohse, M. J. Novel single chain cAMP sensors for receptor-induced signal propagation. J. Biol. Chem. 279, 37215-37218 (2004).
17. Liu, S., Zhang, J. & Xiang, Y. K. FRET-based direct detection of dynamic protein kinase A activity on the sarcoplasmic reticulum in cardiomyocytes. Biochem. Biophys. Res. Commun. 404, 581-586 (2011).
18. Börner, S. et al. FRET measurements of intracellular cAMP concentrations and cAMP analog permeability in intact cells. Nat. Protoc. 6, 427-438 (2011).
19. Calebiro, D. et al. Persistent cAMP-signals triggered by internalized G-proteincoupled receptors. PLoS Biol. 7, e1000172 (2009).
20. Abi-Gerges, A. et al. Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. Circ. Res. 105, 784-792 (2009).
21. Chakir, K. et al. Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart. Sci. Transl. Med. 3, 100ra188 (2011).
22. Direnberger, S. et al. Biocompatibility of a genetically encoded calcium indicator in a transgenic mouse model. Nat. Commun. 3, 1031 (2012).
23. Kamioka, Y., Sumiyama, K., Mizuno, R. & Matsuda, M. Live imaging of transgenic mice expressing FRET biosensors. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2013, 125-128 (2013).
24. Thunemann, M. et al. Transgenic mice for cGMP imaging. Circ. Res. 113, 365-371 (2013).
25. Kadambi, V. J. et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J. Clin. Invest. 97, 533-539 (1996).
26. Kiriazis, H. & Kranias, E. G. Genetically engineered models with alterations in cardiac membrane calcium-handling proteins. Annu. Rev. Physiol. 62, 321-351 (2000).
27. Kuschel, M. et al. beta2-adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart. Circulation 99, 2458-2465 (1999).
28. Nikolaev, V. O., Bunemann, M., Schmitteckert, E., Lohse, M. J. & Engelhardt, S. Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ. Res. 99, 1084-1091 (2006).
29. Nikolaev, V. O. et al. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 327, 1653-1657 (2010).
30. Terrin, A. et al. PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. J. Cell Biol. 175, 441-451 (2006).
31. Lehnart, S. E. et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123, 25-35 (2005).
32. Mehel, H. et al. Phosphodiesterase-2 Is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes. J. Am. Coll. Cardiol. 62, 1596-1606 (2013).
33. Beca, S. et al. Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ. Res. 112, 289-297 (2013).
34. Beca, S. et al. Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ current. Circ. Res. 109, 1024-1030 (2011).
35. Zakhary, D. R., Moravec, C. S. & Bond, M. Regulation of PKA binding to AKAPs in the heart: alterations in human heart failure. Circulation 101, 1459-1464 (2000).
36. Stangherlin, A. et al. Analysis of compartmentalized cAMP: a method to compare signals from differently targeted FRET reporters. Methods Mol. Biol. 1071, 59-71 (2014).
37. Buitrago, M. et al. The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat. Med. 11, 837-844 (2005).
38. Götz, K. R. et al. Transgenic mice for real-time visualization of cGMP in intact adult cardiomyocytes. Circ. Res. 114, 1235-1245 (2014).
39. Sprenger, J. U., Perera, R. K., Götz, K. R. & Nikolaev, V. O. FRET microscopy for real-time monitoring of signaling events in live cells using unimolecular biosensors. J. Vis. Exp. 66, e4081 (2012).
40. Hu, P. et al. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am. J. Physiol. Heart Circ. Physiol. 285, H1261-H1269 (2003).
41. Thompson, W. J. & Appleman, M. M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10, 311-316 (1971).
42. Wagner, E. et al. Stimulated emission depletion live-cell super-resolution imaging shows proliferative remodeling of T-tubule membrane structures after myocardial infarction. Circ. Res. 111, 402-414 (2012).